JP2011513377A5 - - Google Patents

Download PDF

Info

Publication number
JP2011513377A5
JP2011513377A5 JP2010549209A JP2010549209A JP2011513377A5 JP 2011513377 A5 JP2011513377 A5 JP 2011513377A5 JP 2010549209 A JP2010549209 A JP 2010549209A JP 2010549209 A JP2010549209 A JP 2010549209A JP 2011513377 A5 JP2011513377 A5 JP 2011513377A5
Authority
JP
Japan
Prior art keywords
compound
compounds
pharmaceutical composition
integer
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010549209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513377A (ja
JP5657394B2 (ja
Filing date
Publication date
Priority claimed from GBGB0804213.7A external-priority patent/GB0804213D0/en
Application filed filed Critical
Publication of JP2011513377A publication Critical patent/JP2011513377A/ja
Publication of JP2011513377A5 publication Critical patent/JP2011513377A5/ja
Application granted granted Critical
Publication of JP5657394B2 publication Critical patent/JP5657394B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010549209A 2008-03-06 2009-03-06 疼痛の治療又は予防方法 Expired - Fee Related JP5657394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0804213.7 2008-03-06
GBGB0804213.7A GB0804213D0 (en) 2008-03-06 2008-03-06 A method of printing or preventing pain
PCT/IB2009/000448 WO2009109850A2 (en) 2008-03-06 2009-03-06 A method of treating or preventing pain

Publications (3)

Publication Number Publication Date
JP2011513377A JP2011513377A (ja) 2011-04-28
JP2011513377A5 true JP2011513377A5 (enExample) 2013-04-11
JP5657394B2 JP5657394B2 (ja) 2015-01-21

Family

ID=39327664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010549209A Expired - Fee Related JP5657394B2 (ja) 2008-03-06 2009-03-06 疼痛の治療又は予防方法

Country Status (12)

Country Link
US (2) US8883853B2 (enExample)
EP (1) EP2323644B1 (enExample)
JP (1) JP5657394B2 (enExample)
AU (1) AU2009220931B2 (enExample)
CA (1) CA2717692C (enExample)
DK (1) DK2323644T3 (enExample)
ES (1) ES2505325T3 (enExample)
GB (1) GB0804213D0 (enExample)
IL (1) IL207965A (enExample)
PL (1) PL2323644T3 (enExample)
PT (1) PT2323644E (enExample)
WO (1) WO2009109850A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4939396B2 (ja) 2004-03-26 2012-05-23 ノヴァレメッド リミテッド Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法
GB0804213D0 (en) 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
US8802734B2 (en) 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
CN102821761B (zh) * 2009-09-09 2015-06-10 诺瓦麦有限公司 用于治疗疼痛和炎症的n-取代的苯丙酰胺或苯丙烯酰胺
GB201116335D0 (en) * 2011-09-21 2011-11-02 Novaremed Ltd A method of treating or preventing affective disorders
AU2012348529B2 (en) * 2011-12-08 2017-03-30 Novaremed Ltd. Isolated stereoisomeric forms of (S) 2-N (3-O-(propan 2-ol) -1-propyl-4-hydroxybenzene) -3-phenylpropylamide
SG11202111773QA (en) 2019-01-23 2021-11-29 Novaremed Ltd Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
EP3939578A1 (en) 2020-07-13 2022-01-19 Novaremed Ltd. Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2908691A (en) * 1958-07-14 1959-10-13 Searle & Co Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto
GB1037655A (en) * 1964-05-20 1966-08-03 Koninklijke Pharma Fab Nv Di(aralkyl)amines
ZA732136B (en) 1972-04-12 1974-03-27 Lilly Co Eli Dopamine derivatives
JPS5236606A (en) 1975-09-12 1977-03-22 Tanabe Seiyaku Co Ltd Process for preparation of amino compounds
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4908322A (en) * 1985-09-06 1990-03-13 The United States Of America As Represented By The Department Of Health And Human Services Derivatization of amines for electrochemical detection
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
WO1997029079A1 (en) 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
JP2941230B2 (ja) * 1997-05-06 1999-08-25 コナミ株式会社 画像表示処理装置，画像表示処理方法，及びコンピュータプログラムを記録した機械読取り可能な記録媒体
AU2002224139A1 (en) 2000-12-05 2002-06-18 Nippon Chemiphar Co. Ltd. Ppar (peroxisome proliferator activated receptor) activators
JP4667870B2 (ja) * 2002-10-03 2011-04-13 ノヴァレメッド リミテッド 自己免疫疾患、免疫−アレルギー疾患及び臓器又は組織移植拒絶反応の治療において使用する新規な化合物
WO2004047743A2 (en) * 2002-11-22 2004-06-10 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
JP4939396B2 (ja) * 2004-03-26 2012-05-23 ノヴァレメッド リミテッド Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法
DE102004039373A1 (de) * 2004-08-12 2006-02-23 Grünenthal GmbH Para-Alkyl-substituierte N-(4-Hydroxy-3-methoxy-benzyl)-zimtsäureamide und deren Verwendung zur Herstellung von Arzneimitteln
RU2309144C2 (ru) * 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств
PL2026775T3 (pl) 2006-05-09 2015-12-31 Novaremed Ltd Zastosowanie inhibitorów kinazy tyrozynowej Syk w leczeniu komórkowych zaburzeń proliferacyjnych
WO2009039218A2 (en) 2007-09-17 2009-03-26 Chi-Huey Wong Compositions and methods for treating inflammation and inflammation-related disorders by plectranthus amboinicus extracts
GB0804213D0 (en) 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
CN101503370B (zh) 2009-03-02 2012-08-22 上海应用技术学院 一种n-环丙基-反-2-顺-6-壬二烯酸酰胺的合成方法
CN101503373B (zh) 2009-03-13 2013-07-24 山东大学 2-氨基-1-(4-硝基苯基)-1-乙醇类金属蛋白酶抑制剂及其制备方法和用途
US8802734B2 (en) * 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain

Similar Documents

Publication Publication Date Title
JP2011513377A5 (enExample)
JP2010077141A5 (enExample)
JP2009102342A5 (enExample)
JP2013519632A5 (enExample)
JP2021063088A5 (enExample)
JP2009535307A5 (enExample)
JP2013542247A5 (enExample)
JP2016534063A5 (enExample)
JP2010521417A5 (enExample)
JP2011527332A5 (enExample)
JP2013508279A5 (enExample)
JP2011518202A5 (enExample)
JP2012072150A5 (enExample)
JP2007533625A5 (enExample)
JP2013507415A5 (enExample)
JP2009524675A5 (enExample)
JP2013518107A5 (enExample)
JP2012533565A5 (enExample)
JPWO2020123827A5 (enExample)
JP2011507896A5 (enExample)
JP2014505017A5 (enExample)
WO2005000353A1 (ja) 血清コレステロール低下剤或はアテローム性動脈硬化症の予防又は治療剤
CA2648518A1 (en) Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
JP2008534453A5 (enExample)
JP2012508256A5 (enExample)